Cargando…
Thrombotic Thrombocytopenic Purpura Following Pfizer-BioNTech COVID-19 Vaccination in a Patient With Multiple Myeloma: Case Report and Literature Review
The vaccines developed to prevent infection and mitigate morbidity and mortality in patients with COVID-19 demonstrated high efficacy in clinical trials but were associated with adverse events, most of which were mild and transient. However, some adverse events were rather serious, with grave progno...
Autores principales: | Dan, Chitramalya, Sahai, Akshat, Dan, Deepmalya, Sahai, Anmol, Trehan, Ram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633882/ https://www.ncbi.nlm.nih.gov/pubmed/37954740 http://dx.doi.org/10.7759/cureus.46784 |
Ejemplares similares
-
Immune-mediated thrombotic thrombocytopenic purpura following administration of Pfizer-BioNTech COVID-19 vaccine
por: Giuffrida, Gaetano, et al.
Publicado: (2021) -
Thrombocytopenic purpura with AstraZeneca but not Pfizer-BioNTech COVID-19 vaccine
Publicado: (2021) -
COVID-19-Vaccine-Pfizer-BioNTech: Immune thrombocytopenic purpura: case report
Publicado: (2021) -
Immune Thrombocytopenic Purpura Following Pfizer-BioNTech COVID-19 Vaccine in an Elderly Female
por: Jasaraj, Ranjit B, et al.
Publicado: (2021) -
Covid-19-vaccine-pfizer-biontech: Thrombotic thrombocytopenic purpura: case report
Publicado: (2021)